Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.

BCR-ABL fusion oncogene is the molecular hallmark of chronic myelogenous leukemia (CML), a condition characterized by a progression from a chronic to acute phase leukemia because of secondary genetic events, the nature of which remains largely unknown. Here, we report that the expression of the p210 BCR-ABL fusion protein leads to a down-regulation of BRCA1 protein, a gene product involved in the maintenance of genome integrity. BRCA1 protein is nearly undetectable in leukemia cells from patients with CML, both during the chronic phase and in blast crisis. Similarly, stable transfection-enforced expression of p210 protein in established hematopoietic cell lines leads to severe BRCA1 depletion. The lack of significant change in BRCA1 mRNA level in cells expressing p210 supports the hypothesis that the regulation of BRCA1 protein level occurs after transcription. It is abolished on exposure of the cells to STI571 and by mutation in the adenosine triphosphate (ATP) pocket of p210 and thus seems to require the tyrosine kinase activity of BCR-ABL. Cell lines expressing high levels of BCR-ABL display an increased rate of sister chromatid exchange and chromosome aberrations after ionizing radiation. These findings reveal a novel link between the oncoprotein BCR-ABL and the tumor-suppressor protein BRCA1.

[1]  J. Savage,et al.  Dose-response curves for simple and complex chromosome aberrations induced by X-rays and detected using fluorescence in situ hybridization. , 1996, International journal of radiation biology.

[2]  S. Elledge,et al.  BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. , 2000, Genes & development.

[3]  M. Perricaudet,et al.  BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. , 2000, Cancer research.

[4]  R. Jensen,et al.  BRCA1 Expression Restores Radiation Resistance in BRCA1-defective Cancer Cells through Enhancement of Transcription-coupled DNA Repair* , 1999, The Journal of Biological Chemistry.

[5]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[6]  J. Rossant,et al.  The Tumor Suppressor Gene Brca1 Is Required for Embryonic Cellular Proliferation in the Mouse , 1996, Cell.

[7]  A. Ashworth,et al.  Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation , 1997, Nature Genetics.

[8]  S. Ganesan,et al.  Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. , 2001, Molecular cell.

[9]  L. Neckers,et al.  Regulation of BRCA1 by protein degradation , 1999, Oncogene.

[10]  C. Deng.  Roles of BRCA1 in centrosome duplication , 2002, Oncogene.

[11]  P. Mcgale,et al.  Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. , 2000, Blood.

[12]  Atique U. Ahmed,et al.  Mutator phenotype of BCR – ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase β , 1999, Oncogene.

[13]  C. Deng,et al.  Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice. , 2001, Mutation research.

[14]  M. Perricaudet,et al.  Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2 , 1999, Oncogene.

[15]  A. Sandberg,et al.  Sister chromatid exchange in Philadelphia chromosome (Ph1)-positive leukemia. , 1978, Cancer research.

[16]  I. Das,et al.  Expression of p210 bcr/abl increases hematopoietic progenitor cell radiosensitivity. , 1993, International journal of radiation oncology, biology, physics.

[17]  S. Krichevsky,et al.  ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. , 1999, Blood.

[18]  J. Bourhis,et al.  BCR-ABL down-regulates the DNA repair protein DNA-PKcs. , 2001, Blood.

[19]  S. Elledge,et al.  Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. , 1999, Science.

[20]  K. Mills,et al.  No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukaemia blast crisis. , 1994, Leukemia.

[21]  M. Shibuya,et al.  The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Jong-Soo Lee,et al.  hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response , 2000, Nature.

[23]  W. Vainchenker,et al.  Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette , 2001, Leukemia.

[24]  A. Venkitaraman,et al.  Functions of BRCA1 and BRCA2 in the biological response to DNA damage. , 2001, Journal of cell science.

[25]  R. Fishel,et al.  BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. , 2001, Molecular cell.

[26]  T. Mcguire,et al.  Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. , 1999, The Journal of pharmacology and experimental therapeutics.

[27]  D. Livingston,et al.  In search of the tumour-suppressor functions of BRCA1 and BRCA2 , 2000, Nature.

[28]  C. Wada,et al.  Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. , 1994, Blood.

[29]  K. Sobczak,et al.  Structural Determinants of BRCA1 Translational Regulation* , 2002, The Journal of Biological Chemistry.

[30]  C. Wang,et al.  Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. , 1999, Science.

[31]  M. Caligiuri,et al.  BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2 , 2002, Nature Genetics.

[32]  L. Boutis,et al.  Protein tyrosine kinase inhibitor, genistein, enhances apoptosis and cell cycle arrest in K562 cells treated with γ-irradiation , 2000 .

[33]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[34]  B. Calabretta,et al.  The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. , 1998, Blood.

[35]  Ralph Scully,et al.  Dynamic Changes of BRCA1 Subnuclear Location and Phosphorylation State Are Initiated by DNA Damage , 1997, Cell.

[36]  Y. Chen,et al.  BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. , 1996, Cancer research.

[37]  M. Caligiuri,et al.  BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. , 2002, Nature genetics.

[38]  A. Yoshimura,et al.  CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway. , 2001, Experimental hematology.

[39]  J. Minna,et al.  Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. , 1998, Cancer research.

[40]  V. Rotter,et al.  Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia , 1998, Genes, chromosomes & cancer.